Silexion Therapeutics Urges Shareholders to Vote Ahead of March 16 Extraordinary General Meeting
MWN-AI** Summary
Silexion Therapeutics Corp., a clinical-stage biotechnology company focused on oncology, is urging its shareholders to participate in the upcoming Extraordinary General Meeting (EGM) scheduled for March 16, 2026. The meeting is critical as shareholders will vote on key proposals that could significantly impact the company's future, including an increase in authorized share capital and an amendment to its 2024 Equity Incentive Plan.
The proposed authorized share capital increase suggests adding 50 million ordinary shares, raising the total from 9 million to 59 million shares. This adjustment aims to bolster the company's financial standing and support clinical developments, particularly the advancement of the lead product candidate, SIL-204, targeted at treating advanced pancreatic cancer. The amendments to the Equity Incentive Plan propose doubling the annual "evergreen" increase of shares from 5% to 10% of the total issued shares, thereby enhancing Silexion’s ability to attract and retain key personnel essential for achieving long-term growth.
Silexion emphasizes the importance of shareholder votes, as securing a quorum is crucial for proceeding with the EGM. The company's Board of Directors unanimously supports these proposals, believing they are in the best interests of shareholders and crucial for fulfilling Silexion's strategic vision.
Shareholders are encouraged to submit their votes promptly, whether by proxy or online, to ensure their voices are counted. Those with queries regarding the voting process can contact Laurel Hill Advisory Group for assistance. As Silexion charts its course toward advancing innovative treatments in oncology, every vote holds the potential to shape its trajectory and influence shareholder value moving forward.
MWN-AI** Analysis
As Silexion Therapeutics Corp. approaches its Extraordinary General Meeting (EGM) scheduled for March 16, 2026, shareholders are encouraged to actively participate by voting on two significant proposals. The authorization to increase the authorized share capital by 50 million shares and the amendment of the Equity Incentive Plan are pivotal moves that could enhance the company's operational flexibility and long-term growth trajectory.
An increase in authorized share capital can provide Silexion with crucial resources for advancing its clinical pipeline, particularly the development of its lead candidate SIL-204, aimed at targeting hard-to-treat solid tumor cancers driven by the KRAS oncogene. Given the recent positive trends reported in clinical trials, expanding the share capital may also facilitate subsequent financing efforts critical for sustaining research and development.
Moreover, the proposed amendment to the equity incentive plan aims to double the reserved shares for equity-based compensation to 10% of outstanding shares. This change reflects a proactive strategy to attract and retain talent, a critical component for any biotechnology firm striving to navigate the complex landscape of drug development effectively. The implication is clear: a well-incentivized workforce is integral to fostering innovation and operational success.
Investors should consider the potential strategic benefits associated with these proposals against the backdrop of Silexion’s current market position and its clinical development ambitions. Participation in the vote is critical; hence, even shareholders with a modest number of shares should prioritize their involvement to ensure their interests are represented. Overall, endorsing these proposals could bolster Silexion's market position, enhance its growth prospects, and ultimately increase shareholder value. Buyers may find value in this stock ahead of the EGM, given the potential for growth following approval of these strategic initiatives.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Grand Cayman, Cayman Island, March 05, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, reminds its shareholders of the upcoming Extraordinary General Meeting of Shareholders (the "EGM"), scheduled to be held on March 16, 2026.
At the EGM, shareholders will be asked to vote on proposals relating to:
- Authorized Share Capital Increase Proposal: An increase to the authorized share capital of the Company by 50,000,000 ordinary shares, from US$121,500 divided into 9,000,000 ordinary shares of a par value of US$0.0135 each (which is our current authorized share capital), to US$796,500 divided into 59,000,000 ordinary shares of a par value of US$0.0135 each.
- Equity Incentive Plan Evergreen Increase Proposal: An amendment to the Silexion Therapeutics Corp 2024 Equity Incentive Plan (the “2024 Plan”), effective as of January 1, 2026, to increase the number of ordinary shares added annually on January 1st under the “evergreen” provision of Section 5(b)(i) of the 2024 Plan from (i) 5% of the Company’s issued and outstanding ordinary shares, to (ii) such number of ordinary shares as yields a pool of ordinary shares reserved under all equity incentive plans of the Company that constitutes, in the aggregate, 10% of the issued and outstanding ordinary shares on a fully diluted basis..
Your Vote Is Important
By voting FOR all proposals, shareholders will enable the Company to advance its clinical development of SIL-204, advance its long-term strategic vision, including potential strategic initiatives, take actions (if necessary) to maintain compliance with Nasdaq listing requirements, and support the Company’s ability to attract, retain, and incentivize employees, officers, and directors. These proposals, taken together, position the Company to continue executing on its clinical development of SIL-204 strategy while giving the Board the tools necessary to pursue emerging opportunities that may drive future growth and shareholder value.
Every shareholder vote is important, regardless of the number of shares held. The presence of a quorum is required in order for the EGM to proceed, and timely voting by shareholders is essential.
After careful consideration, the Board of Directors has determined that the proposals to be presented at the EGM are in the best interests of the Company and its shareholders and therefore unanimously recommends that shareholders vote FOR all proposed resolutions.
Voting Instructions
Shareholders are strongly encouraged to vote as soon as possible to ensures your shares are represented at the EGM.
- If you lost your proxy card, have any questions or require assistance voting your shares, please contact Laurel Hill Advisory Group, the Company’s proxy solicitor, toll-free at (888) 742?1305 (from the United States and Canada) or at (516) 933?3100 (from other locations).
- Shareholders of record (Registered Shareholder) may vote by returning their proxy card or voting online at www.cstproxyvote.com using the control number provided in their proxy materials.
- If you are a beneficial owner and hold your shares through a broker, please follow the voting instructions provided by your broker, bank, or nominee.
About Silexion Therapuetics
Silexion Therapeutics is a pioneering clinical stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers which have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The Company conducted a Phase 2a clinical trial in its first-generation product which showed a positive trend in comparison to the control of chemotherapy alone. Silexion is committed to pushing the boundaries of therapeutic advancements in the field of oncology, and further developing its lead product candidate for locally advanced pancreatic cancer. For more information please visit: https://silexion.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this communication, including statements regarding the Company’s ability to advance the development of its lead product candidate SIL-204; the Company’s long-term strategic plans and potential strategic initiatives; the Company’s ability to maintain compliance with Nasdaq listing requirements; the potential issuance of additional shares or equity-based incentives; the Company’s ability to attract, retain, and incentivize employees, officers, and directors; and the Company’s future capital requirements and ability to obtain additional financing, are forward-looking statements. These forward-looking statements are generally identified by terminology such as "may", "should", "could", "might", "plan", "possible", "project", "strive", "budget", "forecast", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied in those statements. Important factors that could cause such differences include, but are not limited to: (i) Silexion's ability to successfully complete preclinical studies, proceed with planned regulatory submissions, and initiate clinical trials; (ii) Silexion's strategy, future operations, financial position, projected costs, prospects, and plans; (iii) the impact of the regulatory environment and compliance complexities; (iv) expectations regarding future partnerships or other relationships with third parties; (v) Silexion's future capital requirements and sources and uses of cash, including its ability to obtain additional capital; (vi) Silexion's ability to maintain its Nasdaq listing; and (vii) other risks and uncertainties set forth in the documents filed by the Company with the SEC, including the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 18, 2025. Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date they are made. Silexion undertakes no obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, except as otherwise required by law.
Company Contact:
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
mirit@silexion.com
Investor Relations
Arx Investor Relations
North American Equities Desk
silexion@arxhq.com
FAQ**
How will the proposed Authorized Share Capital Increase for Silexion Therapeutics Corp SLXN impact the company's ability to secure funding for future clinical trials?
What specific strategic initiatives does Silexion Therapeutics Corp SLXN plan to pursue if shareholders approve the Equity Incentive Plan Evergreen Increase Proposal?
How does Silexion Therapeutics Corp SLXN anticipate the increase in authorized share capital will affect shareholder value and company growth in the oncology sector?
In what ways does Silexion Therapeutics Corp SLXN believe that the proposed equity incentive amendments will enhance its ability to attract and retain top talent in its competitive biotech field?
**MWN-AI FAQ is based on asking OpenAI questions about Silexion Therapeutics Corp (NASDAQ: SLXN).
NASDAQ: SLXN
SLXN Trading
8.47% G/L:
$1.92 Last:
29,366 Volume:
$1.95 Open:
